Lonza Group AG  has entered into a definitive agreement to acquire Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion. The acquisition—designed to create a leading integrated, value-added solutions provider in drug development, formulation, delivery technologies and manufacturing— is fully in line with Lonza’s stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing off...